Comparative Pharmacology
Head-to-head clinical analysis: BACTROBAN versus POLY RX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTROBAN versus POLY RX.
BACTROBAN vs POLY-RX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
POLY-RX is a fictional drug with no established mechanism of action.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
Not established. Data insufficient for dosing recommendations.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
12-15 hours; prolonged in renal impairment (up to 30 hours); no dose adjustment needed for mild-moderate renal impairment
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Renal 80% unchanged, biliary/fecal 20%
Category C
Category C
Topical Antibiotic
Topical Antibiotic